The genetic polymorphism of debrisoquine/sparteine metabolism—molecular mechanisms

This publication has 47 references indexed in Scilit:

• MPTP, the neurotoxin inducing parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation
  Biochemical and Biophysical Research Communications, 1987
• Anti-liver-kidney microsome antibody is a marker for the rat hepatocyte endoplasmic reticulum
  Hepatology, 1987
• The P450 Gene Superfamily: Recommended Nomenclature
  DNA, 1987
• Liver disease associated with anti-liver-kidney microsome antibody in children
  The Journal of Pediatrics, 1986
• The molecular mechanisms of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation
  Xenobiotica, 1986
• Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation
  Journal of Molecular Medicine, 1985
• Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism) — Increased michaelis constant (km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizers
  Biochemical and Biophysical Research Communications, 1984
• Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs
  Life Sciences, 1984
• Seroimmunologic Classification of Chronic Hepatitis in 57 Children
  Hepatology, 1983
• Ethnic Differences in Drug Metabolism
  Clinical Pharmacokinetics, 1982